Silver Book Fact

A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Anti-platelet therapy stroke risk reduction
    Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.  
  • “Although high cholesterol was recognized as a key risk factor for cardiovascular disease in the 1970s, there were no good ways to reduce it. The best drug available was…  
  • Every additional dollar spent on the routine use of beta-blockers (versus under-use) in acute heart attack patients has produced health gains valued as high as $38.44.  
  • 5 years of treatment with beta-blockers for heart failure increases patient survival by about 3 1/2 months and patients had fewer overnight hospital stays.